BALDING

REFERENCES

1. Birch MP, Messenger AG. Genetic factors predispose to balding and non-balding in men. Eur J Dermatol. 2001 Jul;11(4):309-14.

2. Stene JJ. [Alopecia areata and treatment]. Rev Med Brux. 2004 Sep;25(4):A282-A285.

3. Price VH. Androgenetic alopecia in adolescents. Cutis. 2003 Feb;71(2):115-21.

4. Hibino T, Nishiyama T. Role of TGF-beta2 in the human hair cycle. J Dermatol Sci. 2004 Jun;35(1):9-18.

5. Hibino T, Nishiyama T. Role of TGF-beta2 in the human hair cycle. J Dermatol Sci. 2004 Jun;35(1):9-18.

6. Whiting DA. Chronic telogen effluvium. Dermatol Clin. 1996 Oct;14(4):723-31.

7. Hadshiew IM, Foitzik K et al. Burden of hair loss: stress and the underestimated psychosocial impact of telogen effluvium and androgenetic alopecia. J Invest Dermatol. 2004 Sep;123(3):455-7.

8. Murray JC. Pregnancy and the skin. Dermatol Clin. 1990 Apr;8(2):327-34.

9. Gollnick H, Blume U et al. [Adverse drug reactions on hair]. Z Hautkr. 1990 Dec;65(12):1128-34.

10. Pierard-Franchimont C, Pierard GE. [How I explore...Hair loss in cancer patients]. Rev Med Liege. 2004 Sep;59(9):525-9.

11. Alexis AF, Dudda-Subramanya R et al. Alopecia areata: autoimmune basis of hair loss. Eur J Dermatol. 2004 Nov;14(6):364-70.

12. Alexis AF, Dudda-Subramanya R et al. Alopecia areata: autoimmune basis of hair loss. Eur J Dermatol. 2004 Nov;14(6):364-70.

13. Yamada K, Goto S. Bilateral subthalamic nucleus stimulation results in reversal of alopecia in Parkinson's disease. Parkinsonism Relat Disord. 2004 Aug;10(6):353-5.

14. Borum ML, Cannava M. Diffuse alopecia associated with omeprazole. Am J Gastroenterol. 1997 Sep;92(9):1576.

15. Sarris E, Tsele E et al. Diffuse alopecia in a hemodialysis patient caused by a low-molecular-weight heparin, tinzaparin. Am J Kidney Dis. 2003 May;41(5):E15.

16. Ettefagh L, Nedorost S et al. Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles. Arch Dermatol. 2004 Aug;140(8):1012.

17. Gottenberg JE, Venancie PY et al. Alopecia areata in a patient with rheumatoid arthritis treated with leflunomide. J Rheumatol. 2002 Aug;29(8):1806-7.

18. Chave TA, Mortimer NJ et al. Agranulocytosis and total scalp alopecia following acitretin. Br J Dermatol. 2003 May;148(5):1063-4.

19. Kohno Y, Ishii A et al. [A case of hair loss induced by carbamazepine]. Rinsho Shinkeigaku. 2004 Jun;44(6):379-81.

20. Gautam M. Alopecia due to psychotropic medications. Ann Pharmacother. 1999 May;33(5):631-7.

21. Shelley ED, Shelley WB. Alopecia and drug eruption of the scalp associated with a new beta-blocker, nadolol. Cutis. 1985 Feb;35(2):148-9.

22. Hashimoto K. The structure of human hair. Clin Dermatol. 1988 Oct;6(4):7-21.

23. Paus R, Foitzik K. In search of the "hair cycle clock": a guided tour. Differentiation. 2004 Dec;72(9-10):489-511.

24. Kaufman KD. Androgens and alopecia. Mol Cell Endocrinol. 2002 Dec 30;198(1-2):89-95.

25. Alexis AF, Dudda-Subramanya R et al. Alopecia areata: autoimmune basis of hair loss. Eur J Dermatol. 2004 Nov;14(6):364-70.

26. Alexis AF, Dudda-Subramanya R et al. Alopecia areata: autoimmune basis of hair loss. Eur J Dermatol. 2004 Nov;14(6):364-70.

27. Drake L, Hordinsky M et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol. 1999 Oct;41(4):550-4.

28. FMPHLSG., The Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol. 2002;12(1):38-49.

29. Pitts WR, Jr. Finasteride (Propecia) and the promotion of high-grade prostate cancer. Arch Dermatol. 2004 Jul;140(7):885-6.

30. Bramson HN, Hermann D et al. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther. 1997 Sep;282(3):1496-502.

31. Ellis CN, Brown MF et al. Sulfasalazine for alopecia areata. J Am Acad Dermatol. 2002 Apr;46(4):541-4.

32. Burke KE. Hair loss. What causes it and what can be done about it. Postgrad Med. 1989 May 1;85(6):52-73, 77.

33. Rushton DH. Nutritional factors and hair loss. Clin Exp Dermatol. 2002 Jul;27(5):396-404.

34. Shimizu Y, Sakai M et al. Immunohistochemical localization of nitric oxide synthase in normal human skin: expression of endothelial-type and inducible-type nitric oxide synthase in keratinocytes. J Dermatol. 1997 Feb;24(2):80-7.

35. Prager N, Bickett K et al. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. J Altern Complement Med. 2002 Apr;8(2):143-52.

36. Liao S, Hiipakka RA. Selective inhibition of steroid 5 alpha-reductase isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate. Biochem Biophys Res Commun. 1995 Sep 25;214(3):833-8.

37. Cos P, De Bruyne T et al. Proanthocyanidins in health care: current and new trends. Curr Med Chem. 2004 May;11(10):1345-59.

38. Neve HJ, Bhatti WA et al. Reversal of Hair Loss following Vertical Gastroplasty when Treated with Zinc Sulphate. Obes Surg. 1996 Feb;6(1):63-5.

39. Uno H, Kurata S. Chemical agents and peptides affect hair growth. J Invest Dermatol. 1993 Jul;101(1 Suppl):143S-7S.